
Last updated: 2026-09-06 18:08:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Werewolf Therapeutics, Inc. (HOWL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,96, with a market capitalisation of $48,52M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,27 to $2,38. This page covers its latest market performance, valuation, price trends and company information.
$48,52M | |
$0,94 | |
$23,99 | |
$0,27 | |
$0,94 | |
465,43K | |
-- | |
-- | |
$2,38 | |
$0,27 | |
-- | |
-- |
Werewolf Therapeutics, Inc. (HOWL) last closed at $0,94 as of 2026-09-05 00:00:00, unchanged from the previous close of $0,94.
During the latest regular trading session, HOWL traded between $0,27 and $23,99, with a volume of 465,43K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Werewolf Therapeutics, Inc. (HOWL) moved from $0,94 to $0,96, representing a gain of 2,99% ($0,03).
The stock traded between $0,93 and $0,97 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1,42 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 32,8%
HOWL is currently trading at $0,96, placing it 32,8% of the way from its 52-week low of $0,27 to its 52-week high of $2,38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Werewolf Therapeutics, Inc. (HOWL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.